

APO-AI/AII PEPTIDE DERIVATIVES

Abstract

The present invention concerns therapeutic agents that mimic the
 5 activity of Apo-AI amphipathic helix peptide. In accordance with the
 present invention, the compounds of the invention comprise:

- a. a Apo-AI amphipathic helix peptide or Apo-AI amphipathic helix
 peptide -mimetic domain, preferably the amino acid sequence of
 SEQ ID NO: 7, or sequences derived therefrom by phage display,
 10 RNA-peptide screening, or the other techniques mentioned above;
 and
- b. a vehicle, such as a polymer (e.g., PEG or dextran) or an Fc domain,
 which is preferred;

wherein the vehicle, preferably an Fc domain, is covalently attached to the
 15 Apo-AI amphipathic helix peptide or Apo-AI amphipathic helix peptide -
 mimetic domain. The vehicle and the Apo-AI amphipathic helix peptide or
 Apo-AI amphipathic helix peptide -mimetic domain may be linked
 through the N- or C-terminus of the Apo-AI amphipathic helix peptide or
 Apo-AI amphipathic helix peptide -mimetic domain, as described further
 20 below. The preferred vehicle is an Fc domain, and the preferred Fc domain
 is an IgG Fc domain. Preferred Apo-AI amphipathic helix peptide or Apo-
 AI amphipathic helix peptide -mimetic domains comprise the amino acid
 sequences described in Table 1. Other Apo-AI amphipathic helix peptide
 or Apo-AI amphipathic helix peptide -mimetic domains can be generated
 25 by phage display, RNA-peptide screening and the other techniques
 mentioned herein.